DGX - Quest Diagnostics Incorporated
112.59 0.00 (0.00%)
After hours: 4:57PM EST
| Previous Close | 112.85 |
| Open | 112.69 |
| Bid | 97.47 x 800 |
| Ask | 112.47 x 800 |
| Day's Range | 111.49 - 112.85 |
| 52 Week Range | 82.59 - 113.00 |
| Volume | 737,064 |
| Avg. Volume | 812,670 |
| Market Cap | 14.937B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | 17.94 |
| EPS (TTM) | 6.28 |
| Earnings Date | Apr 20, 2020 - Apr 26, 2020 |
| Forward Dividend & Yield | 2.24 (1.98%) |
| Ex-Dividend Date | Apr 05, 2020 |
| 1y Target Est | 111.73 |
- Thomson Reuters StreetEvents
Edited Transcript of DGX earnings conference call or presentation 30-Jan-20 1:30pm GMT
Q4 2019 Quest Diagnostics Inc Earnings Call
- Simply Wall St.
Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Investors in Quest Diagnostics Incorporated (NYSE:DGX) had a good week, as its shares rose 2.7% to close at US$111...
- Barrons.com
Marathon Petroleum, Quest Diagnostics, and 9 Other Companies Raise Dividends
Chevron, Alaska Air, and Juniper Networks were some of the other companies that declared dividend increases in a busy week for such announcements.
- Zacks
Quest Diagnostics (DGX) Q4 Earnings Beat, Margins Strong
We are upbeat about Quest Diagnostics' (DGX) expanded network access, which assists the company to expedite volume growth in Q4.
- Benzinga
The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) 10X Genomics Inc (NASDAQ: TXG ) Agile Therapeutics ...
- Simply Wall St.
Would Quest Diagnostics Incorporated (NYSE:DGX) Be Valuable To Income Investors?
Today we'll take a closer look at Quest Diagnostics Incorporated (NYSE:DGX) from a dividend investor's perspective...
- MoneyShow
Quest Diagnostics- A Search for Profits
Quest Diagnostics (DGX) -- which provides diagnostic testing for patients -- is our latest breakout stock, observes technical expert Leo Fasciocco, editor of Ticker Tape Digest.
- Zacks
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?
Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.
- American City Business Journals
From LabCorp to Planet Hollywood: North Carolina's biggest data breaches of 2019
Just-released numbers out of the North Carolina Department of Justice show a record number of data breaches in the state in 2019. The breaches, according to NCDOJ, impacted nearly 1.1 million North Carolinians, a 45 percent decrease from the 1.9 million impacted in 2018. Public records, released at the request of the Triangle Business Journal, highlight the biggest breaches: Jambav, doing business as ToonDoo.com: The comic strip creation website said an estimated 300,654 North Carolinians were impacted, according to what the company told the state.
- American City Business Journals
Memorial Hermann Health System to sell laboratory division
Memorial Hermann Health System, the Houston area's largest health care system, will sell its outreach laboratory division to a major diagnostics company.
- Zacks
Quest Diagnostics to Buy Select Assets of Memorial Hermann
The acquisition is a step forward in Quest Diagnostics' (DGX) commitment toward offering high-quality, cost-efficient diagnostic services in Texas,especially the Houston metropolitan area.
- Zacks
New Alliances Aid Quest Diagnostics Despite Reimbursement Woes
Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.
- PR Newswire
Quest Diagnostics and Memorial Hermann Health System to Broaden Access to Innovative, High-Value Lab Services in Texas
Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Memorial Hermann Health System, a leading not-for-profit health system that includes 17 hospitals and more than 300 care delivery sites in the Greater Houston region, today announced a multi-pronged, long-term collaboration intended to broaden access to innovative, high-value laboratory services for providers and patients in Greater Houston.
- Zacks
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
- PR Newswire
Quest Diagnostics Acquires Blueprint Genetics to Broaden Access to Actionable Insights for Genetic and Rare Diseases
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has acquired Blueprint Genetics in an all-cash equity transaction. Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Financial terms of the transaction were not disclosed.
- PR Newswire
Quest Diagnostics Named One of 2020 "World's Most Admired Companies" by FORTUNE Magazine for Sixth Consecutive Year
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2020 for the sixth consecutive year.
- Zacks
DGX or ADUS: Which Is the Better Value Stock Right Now?
DGX vs. ADUS: Which Stock Is the Better Value Option?
- PR Newswire
Quest Diagnostics To Release Fourth Quarter And Full Year 2019 Financial Results On January 30
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2019 results on Thursday, January 30, 2020, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
- Simply Wall St.
Is There More To Quest Diagnostics Incorporated (NYSE:DGX) Than Its 12% Returns On Capital?
Today we'll look at Quest Diagnostics Incorporated (NYSE:DGX) and reflect on its potential as an investment. To be...
- PR Newswire
Quest Diagnostics To Speak At The 38th Annual J.P. Morgan Healthcare Conference
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 38th Annual J. P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, January 14, 2020 at 7:30 p.m. Eastern Time. Mr. Rusckowski and Mr. Guinan also will participate in a Q&A; session moderated by the host analyst.
- Insider Monkey
How Did Quest Diagnostics Incorporated (DGX) Compare Against Top Hedge Fund Stocks in 2019?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- Zacks
Rosy Outlook for Outpatient and Home Healthcare Industry
Rosy Outlook for Outpatient and Home Healthcare Industry
- Investor's Business Daily
Quest Diagnostics Sees IBD RS Rating Rise To 71
A Relative Strength Rating upgrade for Quest Diagnostics shows improving technical performance. Will it continue?
- Simply Wall St.
Should You Be Pleased About The CEO Pay At Quest Diagnostics Incorporated's (NYSE:DGX)
In 2012 Steve Rusckowski was appointed CEO of Quest Diagnostics Incorporated (NYSE:DGX). This analysis aims first to...
